Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
49
BLFS Quote, Financials, Valuation and Earnings
Last price:
$23.34
Seasonality move
:
11.06%
Day range:
$21.41 - $25.24
52-week range:
$17.70 - $29.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.63x
P/B ratio:
3.14x
Volume:
1.2M
Avg. volume:
664K
1-year change:
29.32%
Market cap:
$1.1B
Revenue:
$82.3M
EPS (TTM):
-$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLFS
BioLife Solutions
|
$22.2M | -$0.04 | -16.97% | -96.3% | $31.33 |
|
IVF
INVO Fertility
|
$1.6M | -- | -8.8% | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
$1.3M | -- | 157.41% | -57.14% | $1.45 |
|
NTRB
Nutriband
|
$665K | -$0.13 | 59.2% | -38.1% | $13.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.34 | -- | -9.68% | $12.50 |
|
SINT
SINTX Technologies
|
$725K | -$0.71 | 20.07% | -96.14% | $30.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions
|
$23.29 | $31.33 | $1.1B | -- | $0.00 | 0% | 13.63x |
|
IVF
INVO Fertility
|
$2.09 | -- | $2.2M | -- | $0.00 | 0% | 0.11x |
|
NMTC
NeuroOne Medical Technologies
|
$0.62 | $1.45 | $19M | -- | $0.00 | 0% | 3.05x |
|
NTRB
Nutriband
|
$5.72 | $13.00 | $63.8M | -- | $0.00 | 0% | 28.36x |
|
NVNO
enVVeno Medical
|
$3.65 | $12.50 | $64M | -- | $0.00 | 0% | 356.07x |
|
SINT
SINTX Technologies
|
$2.59 | $30.00 | $6.5M | -- | $0.00 | 0% | 1.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLFS
BioLife Solutions
|
3.54% | 2.284 | 1.19% | 3.53x |
|
IVF
INVO Fertility
|
-- | 3.433 | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
-- | -0.602 | -- | 2.23x |
|
NTRB
Nutriband
|
1.68% | 3.138 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 0.246 | -- | -- |
|
SINT
SINTX Technologies
|
0.82% | 0.321 | 0.68% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions
|
$15.8M | -$1.2M | -2.93% | -3.1% | -5.09% | $1.6M |
|
IVF
INVO Fertility
|
-- | -- | -- | -- | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$5M | -- | -- | -- | -$4M |
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
BioLife Solutions vs. Competitors
-
Which has Higher Returns BLFS or IVF?
INVO Fertility has a net margin of -1.87% compared to BioLife Solutions's net margin of --. BioLife Solutions's return on equity of -3.1% beat INVO Fertility's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions65.94% -$0.01 $365.6M IVFINVO Fertility-- -- -- -
What do Analysts Say About BLFS or IVF?
BioLife Solutions has a consensus price target of $31.33, signalling upside risk potential of 34.54%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 187.08%. Given that INVO Fertility has higher upside potential than BioLife Solutions, analysts believe INVO Fertility is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions7 0 0 IVFINVO Fertility0 0 0 -
Is BLFS or IVF More Risky?
BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.
-
Which is a Better Dividend Stock BLFS or IVF?
BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or IVF?
BioLife Solutions quarterly revenues are $23.9M, which are larger than INVO Fertility quarterly revenues of --. BioLife Solutions's net income of -$448K is higher than INVO Fertility's net income of --. Notably, BioLife Solutions's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 13.63x versus 0.11x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions13.63x -- $23.9M -$448K IVFINVO Fertility0.11x -- -- --
-
Which has Higher Returns BLFS or NMTC?
NeuroOne Medical Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of 54.53%. BioLife Solutions's return on equity of -3.1% beat NeuroOne Medical Technologies's return on equity of -238.93%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions65.94% -$0.01 $365.6M NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M -
What do Analysts Say About BLFS or NMTC?
BioLife Solutions has a consensus price target of $31.33, signalling upside risk potential of 34.54%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 135.7%. Given that NeuroOne Medical Technologies has higher upside potential than BioLife Solutions, analysts believe NeuroOne Medical Technologies is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions7 0 0 NMTCNeuroOne Medical Technologies1 0 0 -
Is BLFS or NMTC More Risky?
BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.671%.
-
Which is a Better Dividend Stock BLFS or NMTC?
BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or NMTC?
BioLife Solutions quarterly revenues are $23.9M, which are larger than NeuroOne Medical Technologies quarterly revenues of $3.3M. BioLife Solutions's net income of -$448K is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, BioLife Solutions's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 13.63x versus 3.05x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions13.63x -- $23.9M -$448K NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M
-
Which has Higher Returns BLFS or NTRB?
Nutriband has a net margin of -1.87% compared to BioLife Solutions's net margin of -211%. BioLife Solutions's return on equity of -3.1% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions65.94% -$0.01 $365.6M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About BLFS or NTRB?
BioLife Solutions has a consensus price target of $31.33, signalling upside risk potential of 34.54%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 127.27%. Given that Nutriband has higher upside potential than BioLife Solutions, analysts believe Nutriband is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions7 0 0 NTRBNutriband1 0 0 -
Is BLFS or NTRB More Risky?
BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.
-
Which is a Better Dividend Stock BLFS or NTRB?
BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or NTRB?
BioLife Solutions quarterly revenues are $23.9M, which are larger than Nutriband quarterly revenues of $645.8K. BioLife Solutions's net income of -$448K is higher than Nutriband's net income of -$1.4M. Notably, BioLife Solutions's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 13.63x versus 28.36x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions13.63x -- $23.9M -$448K NTRBNutriband28.36x -- $645.8K -$1.4M
-
Which has Higher Returns BLFS or NVNO?
enVVeno Medical has a net margin of -1.87% compared to BioLife Solutions's net margin of --. BioLife Solutions's return on equity of -3.1% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions65.94% -$0.01 $365.6M NVNOenVVeno Medical-- -$0.22 -- -
What do Analysts Say About BLFS or NVNO?
BioLife Solutions has a consensus price target of $31.33, signalling upside risk potential of 34.54%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 242.47%. Given that enVVeno Medical has higher upside potential than BioLife Solutions, analysts believe enVVeno Medical is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions7 0 0 NVNOenVVeno Medical1 0 0 -
Is BLFS or NVNO More Risky?
BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.
-
Which is a Better Dividend Stock BLFS or NVNO?
BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or NVNO?
BioLife Solutions quarterly revenues are $23.9M, which are larger than enVVeno Medical quarterly revenues of --. BioLife Solutions's net income of -$448K is higher than enVVeno Medical's net income of -$4.5M. Notably, BioLife Solutions's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 13.63x versus 356.07x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions13.63x -- $23.9M -$448K NVNOenVVeno Medical356.07x -- -- -$4.5M
-
Which has Higher Returns BLFS or SINT?
SINTX Technologies has a net margin of -1.87% compared to BioLife Solutions's net margin of -882.81%. BioLife Solutions's return on equity of -3.1% beat SINTX Technologies's return on equity of -148.9%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions65.94% -$0.01 $365.6M SINTSINTX Technologies19.79% -$1.26 $3.9M -
What do Analysts Say About BLFS or SINT?
BioLife Solutions has a consensus price target of $31.33, signalling upside risk potential of 34.54%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1058.3%. Given that SINTX Technologies has higher upside potential than BioLife Solutions, analysts believe SINTX Technologies is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions7 0 0 SINTSINTX Technologies1 1 0 -
Is BLFS or SINT More Risky?
BioLife Solutions has a beta of 2.012, which suggesting that the stock is 101.198% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.937%.
-
Which is a Better Dividend Stock BLFS or SINT?
BioLife Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or SINT?
BioLife Solutions quarterly revenues are $23.9M, which are larger than SINTX Technologies quarterly revenues of $192K. BioLife Solutions's net income of -$448K is higher than SINTX Technologies's net income of -$1.7M. Notably, BioLife Solutions's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions is 13.63x versus 1.62x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions13.63x -- $23.9M -$448K SINTSINTX Technologies1.62x -- $192K -$1.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
